| Wolf, Martin |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden |
|
|
| Active, not recruiting | 2 | 98 | Europe | Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO® | Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer | Follicular Lymphoma | 09/23 | 05/26 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology |
|
|
| Completed | N/A | 499 | Europe | | iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG | Advanced Solid Tumors or Hematologic Malignancies | 06/23 | 06/23 | | |
| Recruiting | N/A | 1100 | Europe | | Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx | Immune Thrombocytopenia | 09/26 | 04/27 | | |
| WESTEEL, Virginie |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction |
|
|
| Recruiting | 2/3 | 1360 | Europe | Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization | Intergroupe Francophone de Cancerologie Thoracique, IFCT | Metastatic NSCLC | 01/25 | 06/29 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
NCT04720339: Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. |
|
|
| Recruiting | N/A | 250 | Europe | Molecular monitoring by quantification of cell-free DNA | University Hospital, Strasbourg, France | NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA | 05/25 | 10/27 | | |
NCT04857970: Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon) |
|
|
| Recruiting | N/A | 72 | Europe | Electronic HRQoL questionnaires with feedback to physicians, Paper-pencil HRQoL questionnaires w.o. feedback to physicians | Centre Hospitalier Universitaire de Besancon, University of Franche-Comté, University of Burgundy | Lung Cancer, Non Small Cell Lung Cancer | 11/21 | 08/25 | | |
| PLANCHARD, David |
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 587 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin | AstraZeneca | Non-Small Cell Lung Cancer | 04/23 | 06/26 | | |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Active, not recruiting | 2 | 100 | Europe | DS-1062a | Gustave Roussy, Cancer Campus, Grand Paris, Daiichi Sankyo | Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer | 03/25 | 03/28 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 185 | Europe, Canada, US, RoW | Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608 | GlaxoSmithKline, iTeos Belgium SA | Neoplasms | 07/25 | 07/25 | | |
| Recruiting | 1/2 | 171 | Europe, US, RoW | STX-241 | Pierre Fabre Medicament | Non-small Cell Lung Cancer (NSCLC) | 11/27 | 07/30 | | |
| Recruiting | 1/2 | 200 | Europe, Japan, US, RoW | TAS3351 oral administration | Taiho Oncology, Inc. | Non-Small Cell Lung Cancer | 12/27 | 12/27 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
| Schott, Roland |
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies |
|
|
| Recruiting | 4 | 500 | Europe | Bio-bank repository, Quality of Life (QoL), G-Code | Groupe Francais De Pneumo-Cancerologie | Non Small Cell Lung Cancer, Lung Cancer | 08/26 | 08/28 | | |
NIRVANA-LUNG, NCT03774732: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 327 | Europe, RoW | Radiotherapy, 3D-CRT or SABR, Pembrolizumab, Chemotherapy, Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed | UNICANCER, National Cancer Institute, France | Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4 | 01/26 | 07/27 | | |
| Recruiting | 3 | 486 | Europe | Intensified protocol, Stupp protocol | Centre Oscar Lambret, Association de Neuro-Oncologues d'Expression Francaise, Erasme University Hospital | Glioblastoma | 05/25 | 11/27 | | |
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % |
|
|
| Active, not recruiting | 3 | 349 | Europe | Pembrolizumab, Pembrolizumab and Chemotherapy drugs | University Hospital, Brest, Groupe Français de Pneumo-Cancérologie | Non-small-cell Lung Cancer | 12/25 | 12/25 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 409 | Europe | Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy | Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium, Ministry of Health, France | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 09/28 | 09/31 | | |
| Recruiting | 2 | 80 | Europe, RoW | Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736 | Centre Leon Berard, Groupe Français de Pneumo-Cancérologie | Large Cell Neuroendocrine Carcinoma of the Lung | 09/28 | 09/29 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. |
|
|
| Recruiting | 2 | 455 | Europe | HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib | Centre Leon Berard | Malignant Solid Tumor | 02/26 | 11/26 | | |
PROTECT-06, NCT05128617: Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the Study |
|
|
| Completed | N/A | 20 | Europe | Epirubicin-cyclophosphamide, Epirubicin-endoxan, Paclitaxel, Taxol | Institut de cancérologie Strasbourg Europe, Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire | Breast Cancer | 05/23 | 05/23 | | |
| Recruiting | N/A | 40 | Europe | Cardiac evaluation | Institut de cancérologie Strasbourg Europe, UR 3072 | Breast Cancer | 01/24 | 01/24 | | |
| MAZIERES, Julien |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Active, not recruiting | 2 | 55 | Europe | Nivolumab, BMS-936558-01 | European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation | Thymoma Type B3, Thymic Carcinoma | 12/23 | 07/24 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer |
|
|
| Not yet recruiting | 2 | 152 | Europe | Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance) | Intergroupe Francophone de Cancerologie Thoracique | Stage III NSCLC | 09/28 | 01/32 | | |
| Recruiting | 1/2 | 171 | Europe, US, RoW | STX-241 | Pierre Fabre Medicament | Non-small Cell Lung Cancer (NSCLC) | 11/27 | 07/30 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 250 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
SLEEP_CTC, NCT05988970: Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients |
|
|
| Recruiting | N/A | 27 | Europe | Blood samples will be collected at two times before the treatment initiation: | Institut Claudius Regaud | Lung Cancer | 09/25 | 09/25 | | |
DAMeGe, NCT06589414: Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study |
|
|
| Not yet recruiting | N/A | 171 | Europe | Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP) | Institut Claudius Regaud, Ligue contre le cancer, France | Solid Tumours | 05/26 | 10/26 | | |
MINER, NCT03514368: Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy |
|
|
| Recruiting | N/A | 520 | Europe | Patients treated with immune checkpoint blockade | Institut Claudius Regaud | Solid Cancers | 11/24 | 11/24 | | |
MIRACLE, NCT05732974: A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse |
|
|
| Recruiting | N/A | 60 | Europe | Resected non small cell lung cancer | University Hospital, Toulouse | Non-small Cell Lung Cancer Stage IIIA | 11/25 | 10/26 | | |
LUNG-RESIST, NCT04222335: Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients |
|
|
| Recruiting | N/A | 80 | Europe | Blood samples | University Hospital, Toulouse, Institut National de la Santé Et de la Recherche Médicale, France, National Cancer Institute, France | Lung Cancer, Nonsmall Cell | 12/28 | 12/28 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Recruiting | N/A | 900 | Europe | Blood samples, tumor biopsy specimens and ascites samples will be collected. | Institut Claudius Regaud | Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3, Glioblastoma Multiforme of Brain Stem, Non Small Cell Lung Cancer, Anal Cancer | 09/29 | 09/29 | | |
| Bozorgmehr, Farastuk |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 2 | 50 | Europe | Osimertinib, Tagrisso, Pemetrexed, Cisplatin, Carboplatin | Goethe University | NSCLC Stage IIIB, NSCLC Stage IV | 11/23 | 11/26 | | |
| Active, not recruiting | 2 | 104 | Europe | Atezolizumab, thoracic radiotherapy (TRT) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH | Small Cell Lung Cancer Extensive Stage, Thoracic Radiotherapy | 08/24 | 08/24 | | |
TRADE-hypo, NCT04351256: Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy |
|
|
| Recruiting | 2 | 88 | Europe | Durvalumab Injection [Imfinzi], Thoracic Radiotherapy (TRT) conventionally, Thoracic Radiotherapy (TRT) hypofractionated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, AstraZeneca | NSCLC, Stage III | 10/25 | 06/26 | | |
LCNEC-ALPINE, NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung |
|
|
| Recruiting | 2 | 67 | Europe | Atezolizumab | Technische Universität Dresden, Roche Pharma AG | Large Cell Neuroendocrine Carcinoma of the Lung | 01/28 | 01/29 | | |
| Reinmuth, Niels |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
| Active, not recruiting | 2 | 92 | Europe | Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb | Pleural Mesothelioma Malignant | 12/24 | 01/25 | | |
LCNEC-ALPINE, NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung |
|
|
| Recruiting | 2 | 67 | Europe | Atezolizumab | Technische Universität Dresden, Roche Pharma AG | Large Cell Neuroendocrine Carcinoma of the Lung | 01/28 | 01/29 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
| AUDIGIER-VALETTE, Clarisse |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction |
|
|
| Recruiting | 2/3 | 1360 | Europe | Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization | Intergroupe Francophone de Cancerologie Thoracique, IFCT | Metastatic NSCLC | 01/25 | 06/29 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib |
|
|
| Active, not recruiting | 2 | 150 | Europe | TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis | Nantes University Hospital, AstraZeneca | Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
DEEP-Lung-IV, NCT04994795: Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | N/A | 4000 | Europe, Canada, US, RoW | Predictive models (data collection) | Sophia Genetics SAS | Non-small Cell Lung Cancer Metastatic | 12/24 | 02/25 | | |
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) |
|
|
| Recruiting | N/A | 300 | Europe | Plasma ctDNA, FFPE blocks | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R | 10/31 | 10/31 | | |
PIONEER, NCT04567446: Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach |
|
|
| Recruiting | N/A | 1100 | Europe | Stool, Blood sample | Gustave Roussy, Cancer Campus, Grand Paris | Cancer | 12/24 | 12/24 | | |
| Schutte, Wolfgang |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
